Visfatin affects redox adaptative responses and proliferation in Me45 human malignant melanoma cells: An in vitro study

Oncology Reports

Volumn 29, Issue 2, 2013, Pages 771-778

  Bułdak, Rafał Jakub ^a   Bułdak, Łukasz ^a   Polaniak, Renata ^a   Kukla, Michał ^a   Birkner, Ewa ^a   Kubina, Robert ^a   Kabała Dzik, Agata ^a   Duława Bułdak, Anna ^a   Zwirska Korczala, Krystyna ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Adipocytokines; Antioxidant enzymes; DNA damage; Lipid peroxidation process; Melanoma; Proliferation; Visfatin

Indexed keywords

CATALASE; GLUTATHIONE PEROXIDASE; INSULIN; INSULIN RECEPTOR; MALONALDEHYDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SUPEROXIDE DISMUTASE;

ADAPTIVE IMMUNITY; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID PEROXIDATION; MELANOMA; MELANOMA CELL; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADAPTATION, PHYSIOLOGICAL; ANALYSIS OF VARIANCE; ANTIOXIDANTS; CATALASE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; GLUTATHIONE PEROXIDASE; HUMANS; HYDROGEN PEROXIDE; LIPID PEROXIDATION; MELANOMA; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OXIDATION-REDUCTION; STATISTICS, NONPARAMETRIC; SUPEROXIDE DISMUTASE;

EID: 84872763359     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2175     Document Type: Article

References (42)

1. Tilg H and Moschen AR: Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci 114: 275-288, 2008. (Pubitemid 351294003)
2. Cappellani A, Di Vita M, Zanghi A, Cavallaro A, Piccolo G, Veroux M, Berretta M, Malaguarnera M, Canzonieri V and Lo Menzo E: Diet, obesity and breast cancer: an update. Front Biosci (Schol Ed) 4: 90-108, 2012.
3. Thomas CC, Wingo PA, Dolan MS, Lee NC and Richardson LC: Endometrial cancer risk among younger, overweight women. Obstet Gynecol 114: 22-27, 2009.
4. Larsson SC and Wolk A: Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 97: 1005-1008, 2007. (Pubitemid 47519294)
5. Dennis LK, Lowe JB, Lynch CF and Alavanja MC: Cutaneous melanoma and obesity in the Agricultural Health Study. Ann Epidemiol 18: 214-221, 2008. (Pubitemid 351232237)
6. Oita RC, Ferdinando D, Wilson S, Bunce C and Mazzatti DJ: Visfatin induces oxidative stress in differentiated C2C12 myotubes in an Akt- and MAPK-independent, NFκB-dependent manner. Pflugers Arch 459: 619-630, 2010.
7. Adya R, Tan BK, Punn A, Chen J and Randeva HS: Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 78: 356-365, 2008. (Pubitemid 351556097)
8. Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR, Stumvoll M and Blüher M: Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54: 2911-2916, 2005. (Pubitemid 41401086)
9. Tanaka M, Nozaki M, Fukuhara A, Segawa K, Aoki N, Matsuda M, Komuro R and Shimomura I: Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. Biochem Biophys Res Commun 359: 194-201, 2007. (Pubitemid 46880493)
10. Garten A, Petzold S, Barnikol-Oettler A, Körner A, Thasler WE, Kratzsch J, Kiess W and Gebhardt R: Nicotinamide phosphoribo-syltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochem Biophys Res Commun 391: 376-381, 2010.
11. Friebe D, Neef M, Kratzsch J, Erbs S, Dittrich K, Garten A, Petzold-Quinque S, Blüher S, Reinehr T, Stumvoll M, Blüher M, Kiess W and Körner A: Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia 12: 1200-1211, 2011.
12. Laudes M, Oberhauser F, Schulte DM, Freude S, Bilkovski R, Mauer J, Rappl G, Abken H, Hahn M, Schulz O and Krone W: Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans. Horm Metab Res 42: 268-273, 2010.
13. Dahl TB, Yndestad A, Skjelland M, Øie E, Dahl A, Michelsen A, Damås JK, Tunheim SH, Ueland T, Smith C, Bendz B, Tonstad S, Gullestad L, Frøland SS, Krohg-Sørensen K, Russell D, Aukrust P and Halvorsen B: Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 115: 972-980, 2007. (Pubitemid 46328290)
14. Sommer G, Garten A, Petzold S, Beck-Sickinger AG, Blüher M, Stumvoll M and Fasshauer M: Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clin Sci 115: 13-23, 2008. (Pubitemid 351930789)
15. Dahl TB, Holm S, Aukrust P and Halvorsen B: Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology. Annu Rev Nutr 32: 229-243, 2012.
16. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H and Tilg H: Visfatin, an adipocytokine with proin-fammatory and immunomodulating properties. J Immunol 178: 1748-1758, 2007. (Pubitemid 46154646)
17. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y and Shimomura I: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307: 426-430, 2005. (Pubitemid 40139988)
18. Imai S: Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases. Curr Pharm Des 15: 20-28, 2009.
19. Shackelford RE, Bui MM, Coppola D and Hakam A: Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers. Int J Clin Exp Pathol 3: 522-527, 2010.
20. Reddy PS, Umesh S, Thota B, Tandon A, Pandey P, Hegde AS, Balasubramaniam A, Chandramouli BA, Santosh V, Rao MR, Kondaiah P and Somasundaram K: PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biol Ther 7: 663-668, 2008.
21. Patel ST, Mistry T, Brown JE, Digby JE, Adya R, Desai KM and Randeva HS: A novel role for the adipokine visfatin/pre-B cell colony-enhancing factor 1 in prostate carcinogenesis. Peptides 31: 51-57, 2010.
22. Park SH, Ozden O, Jiang H, Cha YI, Pennington JD, Aykin-Burns N, Spitz DR, Gius D and Kim HS: Sirt3, mitochondrial ROS, ageing, and carcinogenesis. Int J Mol Sci 12: 6226-6239, 2011.
23. Kong W, Kuester RK, Gallegos A and Sipes IG: Induction of DNA damage in human urothelial cells by the brominated flame retardant 2,2-bis(bromomethyl)-1, 3-propanediol: role of oxidative stress. Toxicology 290: 271-277, 2011.
24. Angeli J P, Garcia CC, Sena F, Freitas F P, Miyamoto S, Medeiros MH and Di Mascio P: Lipid hydroperoxide-induced and hemoglobin-enhanced oxidative damage to colon cancer cells. Free Radic Biol Med 51: 503-515, 2011.
25. Hegde ML, Hazra TK and Mitra S: Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells. Cell Res 18: 27-47, 2008.
26. Trachootham D, Alexandre J and Huang P: Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8: 579-591, 2009.
27. Kramer-Marek G, Serpa C, Szurko A, Widel M, Sochanik A, Snietura M, Kus P, Nunes RM, Arnaut LG and Ratuszna A: Spectroscopic properties and photodynamic effects of new lipophilic porphyrin derivatives: efficacy, localisation and cell death pathways. J Photochem Photobiol B 84: 1-14, 2006. (Pubitemid 43842708)
28. Paglia DE and Valentine WN: Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70: 158-169, 1967.
29. Paoletti F and Mocali A: Determination of superoxide dismutase activity by purely chemical system based on NAD(P)H oxidation. Methods Enzymol 186: 209-220, 1990. (Pubitemid 20279958)
30. Aebi H: Catalase in vitro. Methods Enzymol 105: 121-126, 1984.
31. Placer ZA, Cushman LL and Johnson BC: Estimation of product of lipid peroxidation (malonyl dialdehyde) in biochemical systems. Anal Biochem 16: 359-364, 1966.
32. 125IdUrd. Int J Radiat Biol 64: 349-356, 1993.
33. Turrens JF: Mitochondrial formation of reactive oxygen species. J Physiol 552: 335-344, 2003. (Pubitemid 37321833)
34. Polaniak R, Bułdak RJ, Karoń M, Birkner K, Kukla M, Zwirska-Korczala K and Birkner E: Influence of an extremely low frequency magnetic field (ELF-EMF) on antioxidative vitamin E properties in AT478 murine squamous cell carcinoma culture in vitro. Int J Toxicol 29: 221-230, 2010.
35. Samuels BL, Murray JL, Cohen MB, Safa AR, Sinha BK, Townsend AJ, Beckett MA and Weichselbaum RR: Increased glutathione peroxidase activity in a human sarcoma cell line with inherent doxorubicin resistance. Cancer Res 51: 521-527, 1991.
36. Lenehan PF, Gutiérrez PL Wagner JL, Milak N, Fisher GR and Ross DD: Resistance to oxidants associated with elevated catalase activity in HL-60 leukemia cells that overexpress multidrug-resistance protein does not contribute to the resistance to daunorubicin manifested by these cells. Cancer Chemother Pharmacol 35: 377-386, 1995.
37. Gaweł S, Wardas M, Niedworok E and Wardas P: Malondialdehyde (MDA) as a lipid peroxidation marker Wiad Lek 57: 453-455, 2004.
38. Wang P, Xu TY, Guan YF, Su DF, Fan GR and Miao CY: Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res 81: 370-380, 2009.
39. Xie H, Tang SY, Luo XH, Huang J, Cui RR, Yuan LQ, Zhou HD, Wu XP and Liao EY: Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int 80: 201-210, 2007. (Pubitemid 46411878)
40. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M and Ludvik B: Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 91: 1578-1581, 2006.
41. Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR, Milbrandt J, Kiess W and Imai S: Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 6: 363-375, 2007. (Pubitemid 350011996)
42. Kim SR, Bae YH, Bae SK, Choi KS, Yoon KH and Koo TH: Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta 1783: 886-895, 2008.